

NANETS2020  
MULTIDISCIPLINARY NET MEDICAL VIRTUAL  
**SYMPOSIUM**



#NANETSGOESVIRTUAL

OCTOBER 2020

## Virtual Poster Hall

### Category 1: Basic Science

Poster Number	Category ID	Poster Title	Poster Presenter	Abstract ID
1	B-1	Metastatic Pancreatic Neuroendocrine Tumors Have Decreased Somatostatin Expression and Increased Akt Signaling	Catherine Tran, MD, University of Iowa, Department of Surgery	104
2	B-2	Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms	Kevin Yang, BS, BC Cancer, Canada's Michael Smith Genome Sciences Centre	105
3	B-3	Telotristatethyl augments cytotoxic chemotherapy response in preclinical tumor models	Niranjan Awasthi, PhD, Indiana University School of Medicine - South Bend	120
4	B-4	Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest	Mark Kidd, Wren Laboratories	158
5	B-5	Exploring Plasma-Derived Exosomes (PDEs) as a Response Biomarker in Neuroendocrine Tumors (NETs)	Medhavi Gupta, MD, Roswell Park Cancer Center, Department of Medicine	177
6	B-6	The anti-proliferative effects of the mycotoxin Verrucaric acid on neuroendocrine tumor cells	Jason Whitt, PhD, UAB, Department of Surgery	182
7	B-7	MAML3 overexpression increases tumorigenicity in several neuroendocrine tumor types	Lauren Fishbein, MD, PhD, University of Colorado School of Medicine,	187
8	B-8	The lineage transcription factors ASCL1, NKX2-1, and PROX1 form a regulatory network and control the expression of the ion channel, SCN3A, in small cell lung cancer.	Karine Pozo, PhD, UT Southwestern Medical Center	195
9	B-9	5-Azacytidine inhibits neuroendocrine tumors via the induction of Notch3 by the transactivator BORIS	Rui Zheng-Pywell, MD, University of Alabama Birmingham	203

## Category 2: Applied Basic Science

Poster Number	Category ID	Poster Title	Poster Presenter	Abstract ID
10	B-10	The Importance of Dedicated Nurse Navigation for PRRT Therapy	Rebecca Mirro, BSN, RN, UCSF, GI Oncology	29
11	B-11	Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma	Akihiro Ohmoto, MD, PhD, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Division of Medical Oncology	101
12	B-12	Functional genetic screen to identify drivers of pancreatic neuroendocrine tumor pathogenesis	Chandra Kumar Maharjan, BS, The University of Iowa, Neuroscience and Pharmacology	132
13	B-13	Efficacy of combined MEK and CDK targeted therapies for pancreatic neuroendocrine tumors	Ume Salma Shaik Amjad, PhD, University of Iowa, Neuroscience and Pharmacology	146
14	B-15	Mapping anti-angiogenic proteome associated with black raspberry extract and gallic acid in neuroendocrine cancer	Nicholas Skill, PhD, Indiana University, Surgery	179
15	B-16	A Systematic Workflow to Identify Anti-cancer Drugs Targeting Small Bowel Neuroendocrine Tumors and Neuroendocrine Carcinomas	Po Hien Ear, PhD, University of Iowa, Department of Surgery	196
16	B-17	Preclinical Evaluation of Radionuclide Therapy Targeting CXCR4 and Thioredoxin Reductase in Atypical Carcinoid and Neuroendocrine Carcinoma	Dijie Liu, PhD, University of Iowa	198

## Category 3: Clinical—Chemotherapy, SSA and Biologics

Poster Number	Category ID	Poster Title	Poster Presenter	Abstract ID
17	C-1	Preliminary Safety, PK/PD, and Antitumor Activity of XmAb18087, an SSTR2 x CD3 Bispecific Antibody, in Patients with Advanced Neuroendocrine Tumors	Bassel El-Rayes, MD, Winship Cancer Institute at Emory University, Hematology and Oncology	111
18	C-2	Real-World Observational Study of Somatostatin Analogs and Rescue Medication Use for Neuroendocrine Tumors in Canada	Daniel Rayson, MD, Nova Scotia Cancer Center, Dalhousie University	112
19	C-3	Patient-Reported Activity Impairment, Work Productivity Loss, and Carcinoid Syndrome Outcomes: Interim Analyses of the XERMELO Patient Registry	Christina Darden, BS, RTI Health Solutions	113
20	C-4	Carcinoid Syndrome (CS) Improvements in Patients Receiving Telotristat Ethyl (TE): Findings from TELEPRO-II	Matthew Kulke, MD, Boston University/Boston Medical Center	115
21	C-5	Efficacy of Telotristat Ethyl (TE) in Patients with Progressive Neuroendocrine Tumor Disease: Real World Clinical Practice Experience	Eric Liu, MD, The Neuroendocrine Institute at Rocky Mountain Cancer Centers	117
22	C-6	Efficacy of checkpoint inhibitors in neuroendocrine neoplasms: the Mayo Clinic experience	Jennifer Gile, MD, Mayo Clinic College of Medicine, Division of Medical Oncology, Department of Oncology	125
23	C-7	Safety in patients with neuroendocrine tumors receiving telotristat ethyl (TE) with peptide receptor radionuclide therapy (PRRT)	Aman Chauhan, MD, University of Kentucky Markey Cancer Center	130
24	C-8	Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study	Marianne Pavel, PhD, Friedrich Alexander University Erlangen-Nürnberg, Department of Medicine	135
25	C-9	Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Midgut Neuroendocrine Tumors (NETs): CLARINET FORTE Study	Marianne Pavel, PhD, Friedrich Alexander University Erlangen-Nürnberg, Department of Medicine	136

Poster Number	Category ID	Poster Title	Poster Presenter	Abstract ID
26	C-10	Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors	Alex Liu, MD, Mayo Clinic	143
27	C-11	Comparative Analysis of Octreotide Long Acting Release (LAR) and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Single Institution Experience.	Amr Mohamed, MD, UH Seidman Cancer Center, Case Western Reserve University, Division of Hematology and Medical Oncology	149
28	C-12	A Single-Centre Pilot Study for Radiosensitization of Everolimus with External Beam Radiotherapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis	Sten Myrehaug, MD, University of Toronto, Radiation Oncology	152
29	C-13	Efficacy of FOLFOX with or without bevacizumab in patients with aggressive pancreatic NETs after prior capecitabine/temozolomide	Taymeyah Al-Toubah, MPH, H. Lee Moffitt Cancer Center & Research Institute, Gastrointestinal Oncology	156
30	C-14	Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms	Taymeyah Al-Toubah, MPH, H. Lee Moffitt Cancer Center & Research Institute, Gastrointestinal Oncology	157
31	C-15	Concurrent Everolimus with Hepatic Transarterial Bland Embolotherapy (Evero-Embo) in Patients with Metastatic Well Differentiated Neuroendocrine Tumor (NET)	Lowell Anthony, MD, University of Kentucky, Internal Medicine/Medical Oncology	159
32	C-16	Comparative outcomes of second line topoisomerase I inhibitor-containing therapies on extrapulmonary neuroendocrine carcinoma	Ho-Man Yeung, MD, Fox Chase Cancer Center	162
33	C-17	The Clinical Impact of Serum Chromogranin-A in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS).	Amr Mohamed, MD, UH Seidman Cancer Center, Case Western Reserve University, Division of Hematology and Medical Oncology	163
34	C-18	Avelumab in Unresectable/Metastatic, Progressive, Grade 2-3 neuroendocrine neoplasms (NEN): Combined results from NET-001 and NET-002 trials	David Chan, MBBS, University of Toronto, Medicine	164
35	C-19	Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review	Bryan Le, BS, University of California, San Francisco, Gastrointestinal Oncology	185
36	C-20	Efficacy of somatostatin analog (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs)	Patrick McGarrah, MD, Mayo Clinic, Division of Medical Oncology, Department of Oncology	200

#### Category 4: Clinical—PRRT/Nuclear Medicine/Interventional Radiology/Imaging

Poster Number	Category ID	Poster Title	Poster Presenter	Abstract ID
37	C-21	Efficacy and safety of peptide receptor radionuclide therapy in lung neuroendocrine tumors: a multicentre study	Amir Iravani, MD, Peter MacCallum Cancer Centre, Molecular Imaging and Therapeutic Nuclear Medicine, ENETS Centre of Excellence	15
38	C-22	Patient Travel Concerns After Treatment with Peptide Receptor Radionuclide Therapy (PRRT)	Ayse Kendi, MD, Mayo Clinic, Department of Radiology	36
39	C-23	<sup>177</sup> Lu-DOTATATE/DOTATOC re-treatment in patients with progressive neuroendocrine tumours: a systematic review and meta-analysis	Jonathan Strosberg, MD, Moffitt Cancer Center	43

40	C-24	A Clinical Score(CS) for Well-Differentiated Neuroendocrine Tumor(WD-NET) Patients(Pts) Undergoing Peptide Receptor Radionuclide Therapy(PRRT)	Satya Das, MD, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center	44
41	C-25	The Use of Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Neuroendocrine Tumor Cardiac Metastases	Irene Yu, MD, BC Cancer	58
42	C-26	Safety of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumors: Data from a US Expanded Access Program	Edward Wolin, MD, Icahn School of Medicine at Mount Sinai, Center for Carcinoid and Neuroendocrine Tumors at the Tish Cancer Institute	118
43	C-27	Re-treatment with 177Lu-DOTATATE in patients with neuroendocrine tumors: multicenter real-world experience	Shaunak Navalkisoor, MD, Royal Free London NHS Foundation Trust	119
44	C-28	Supportive Management during PRRT for Symptomatic Pheochromocytomas or Paragangliomas	Erica Tsang, MD, University of British Columbia, Medical Oncology	134
45	C-29	Gallium-68 Dotatate PET/CT (Ga68PET/CT) versus contrast enhanced cross sectional imaging (CECSI) to measure treatment response (TR) to peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine tumors (NETs).	Dane Jackson, MD, Virginia Mason Medical Center, Radiology	145
46	C-30	64Cu-DOTATATE PET in neuroendocrine tumor patients: what we learned from the first 1,200 patients	Andreas Kjaer, MD, PhD, Rigshospitalet & University of Copenhagen, Clinical Physiology, Nuclear Medicine & PET	147
47	C-31	PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest	Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center	160
48	C-32	Dynamic Contrast-Enhanced CT to Evaluate Response in Neuroendocrine Liver Metastases Treated with Everolimus and Radiation	John Hudson, MD, PhD, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Radiation Oncology	165
49	C-33	Association Between Surveillance Imaging and Survival Outcomes in Small Bowel Neuroendocrine Tumors	Akie Watanabe, MD, University of British Columbia	167
50	C-34	An Initial Experience in Establishing a Theranostic Precision Medicine PRRT Targeted Radiotherapy Program for the Treatment of GEP-NETs with Lu-177 Dotatate (Lutathera) in a Major Academic University Hospital.	Patrick Wojtylak, BS, University Hospitals of Cleveland, Cleveland Medical Center, Nuclear Medicine/Radiology	173
51	C-35	Real-world analysis of safety and tolerance of repeat peptide receptor radionuclide therapy.	Justin Chau, MD, University of Iowa Hospitals and Clinics, Hematology, Oncology, and Bone Marrow Transplantation	192
52	C-36	212Pb-AlphaMedix™ Targeted Alpha Therapy (TAT): A potential breakthrough in treatment of metastatic SSTR expressing NET.	Ebrahim Delpassand, MD, RadioMedix, , 9701 Richmond Ave. Suite #222, 77042, Houston, US	193
53	C-37	Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET)	Heying Duan, MD, Stanford University, Radiology, Division of Nuclear Medicine and Molecular Imaging	194
54	C-38	Hepatotoxicity in Previously Treated Y-90 Metastatic Neuroendocrine Cancer Patients after PRRT: Single Institution Experience	Aditya Shreenivas, MD, Medical College of Wisconsin, Hem/Onc	197
55	C-39	Hematotoxicity of peptide receptor radionuclide therapy (PRRT) – a single institution experience	Yee Lan Wong, PA-C, Medical College of Wisconsin	199
56	C-40	Renal and hepatotoxicity of peptide receptor radionuclide therapy (PRRT) – a single institution experience	Heying Duan, MD, Stanford University, Radiology, Division of Nuclear Medicine and Molecular Imaging	201

## Category 5: Clinical—Surgical-Applied Pathology

Poster Number	Category ID	Poster Title	Poster Presenter	Abstract ID
57	C-41	Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: an international dual-institutional study	Yosuke Kasai, MD, PhD, Kyoto University, Surgery	12
58	C-42	Response Rates in Metastatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy and Implications for Future Treatment Strategies	Tanaz Vaghaiwalla, MD, University of Chicago Medical Center, Surgery	13
59	C-43	Ultrasound-guided percutaneous ethanol ablation for loco-regional recurrence of Medullary Thyroid Cancer	Thomas Szabo Yamashita, MD, Mayo Clinic	46
60	C-44	ISL-1 expression is a prognostic marker in patients with well-differentiated pancreatic neuroendocrine tumors	Hussein Assi, MD, Boston University/Boston Medical Center, Hematology/Oncology	62
61	C-45	It's Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors	Catherine Tran, MD, University of Iowa, Department of Surgery	103
62	C-46	Symptom and Quality Of Life Impairments in Cushing's Disease Before and After Endoscopic Transsphenoidal Surgery	Tony Huang, BS, St. Michael's Hospital, Division of Neurosurgery	107
63	C-47	Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems	Heather Wachtel, MD, University of Pennsylvania, Surgery	127
64	C-48	Metabolic changes in pheochromocytoma and paraganglioma: correlation between plasma hormone levels, weight and diabetes	Lauren Krumeich, MD, University of Pennsylvania, Surgery	128
65	C-49	Pattern of Disease Recurrence and Treatment after Surgery for Nonfunctioning Well-Differentiated Pancreatic Neuroendocrine Tumors (NF-PanNET)	Valentina Andreasi, MD, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Pancreatic Surgery Unit, Pancreas Translational & Clinical Research Center	150
66	C-50	Socioeconomic Disparities in Midgut Neuroendocrine Tumors (MNETs): An NCDB Analysis	Timothy Diperi, MD, Cedars Sinai Medical Center, Department of Surgery	169
67	C-51	A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors	Yosuke Kasai, MD, PhD, Kyoto University, Surgery	172
68	C-52	Upfront Interventional Treatments Prior to Liver-progression for Small Bowel Neuroendocrine Liver Metastasis	Yosuke Kasai, MD, PhD, Kyoto University, Surgery	174
69	C-53	Well-Differentiated Rectal Neuroendocrine Tumors: Analysis of Histology, Including INSM1 Expression, and Biologic Behavior, Involving a Large Cohort of 94 Cases	Ryan Sappenfield, MD, Washington University in St. Louis, Pathology and Immunology	181
70	C-54	Survival After Resection of Poorly Differentiated Gastroenteropancreatic Neuroendocrine Neoplasm: Association of Nodal Involvement and Survival	Lucas Thornblade, MD, MPH, City of Hope National Medical Center, Department of Surgery	190
71	C-55	The Proliferative Indices of the Primary Ileal Well-Differentiated Neuroendocrine Tumors, Corresponding Lymph Nodes/Mesenteric Deposits, and Distant Metastatic Sites Show Poor Correlation	Jane Lee, MD, Washington University, Pathology and Immunology	204

## Category 6: Population Science

Poster Number	Category ID	Poster Title	Poster Presenter	Abstract ID
72	P-1	Cross-sectional study assessing the feasibility of using NET VITALS communication tool among patients with neuroendocrine tumors	Daneng Li, MD, City of Hope	37
73	P-2	Trends in the Incidence and Survival Outcomes in Patients With Lung Neuroendocrine Neoplasms in the United States	Shrunjal Shah, MD, Roswell Park Comprehensive Cancer Center, Department of Internal Medicine/ Hematology & Medical Oncology	73
74	P-3	Upfront small bowel resection for small bowel neuroendocrine tumors with synchronous metastases: a propensity matched comparative population-based analysis	Sean Bennett, MD, University of Toronto, Surgery	76
75	P-4	Mapping the Patient Journey to Neuroendocrine Tumor (NET) Diagnosis Using Real-World Data (RWD)	David Ray, PharmD, MBA, MPH, Ipsen	98
76	P-5	Costs Associated with Misdiagnoses of Neuroendocrine Tumors (NET)	Alexandria Phan, MD, UT Health North Campus	99
77	P-6	Real World Analysis of Misdiagnosis Among Patients with Neuroendocrine Tumors (NET)	Callisia Clarke, MD, Medical College of Wisconsin	100
78	P-7	Retrospective analysis of DIPNECH and carcinoid tumorlets progressing to invasive pulmonary carcinoid tumors	Thomas Yang Sun, MD, Stanford School of Medicine, Division of Oncology	140
79	P-8	Breakthrough Symptoms Remain an Unmet Need in Symptomatic Patients with Neuroendocrine Tumors	Eric Liu, MD, The Neuroendocrine Institute at Rocky Mountain Cancer Centers	175
80	P-9	Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors (NETs): A population-based analysis.	Julie Hallet, MD, University of Toronto, Surgery	180
81	P-10	A Neuroendocrine Tumor (NET) Patient Survey of Experiences with Telemedicine during the COVID-19 Pandemic	Yvette Mattison, PhD, New Orleans Louisiana Neuroendocrine Tumor Specialists	183

## Category 7: Other Research

Poster Number	Category ID	Poster Title	Poster Presenter	Abstract ID
82	O-1	Neuroendocrine Wellness Clinic- holistic care delivery to patients with metastatic neuroendocrine tumors	Angela Laffan, NP, University of California San Francisco, GI Medical Oncology/Survivorship	79
83	O-2	Development and Validation of the Disease-Specific QOL-CD Quality of Life Questionnaire for Patients with Cushing's Disease	Tony Huang, BS, St. Michael's Hospital, Division of Neurosurgery, 30 Bond Street, M5B 1W8, Toronto, CA	108
84	O-3	Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN) – USA and Canada vs Global Diagnosis of NETs	Teodora Kolarova, MD, International Neuroendocrine Cancer Alliance	126
85	O-4	Identifying care processes promoting person-centred care for patients diagnosed with neuroendocrine tumours (NETs)	Julie Hallet, MD, University of Toronto, Surgery	129
86	O-5	Supporting accurate patient information for an uncommon malignancy: evaluation of the quality of information on neuroendocrine tumors (NETs) on the internet	Safa Sohail, BS, Sunnybrook Research Institute	131

Poster Number	Category ID	Poster Title	Poster Presenter	Abstract ID
87	O-6	Diagnostic Effectiveness of Chromogranin A and Multigene Liquid Biopsy (NETest) in Neuroendocrine Neoplasia: An assessment of Monoanalyte and Multianalyte Biomarker Efficacy	Anna Malczewska, MD, PhD, Medical University of Silesia, Department of Endocrinology and Neuroendocrine Tumors, ENETS Center of Excellence	153
88	O-7	Stereotactic Ablative Radiotherapy for the Management of Neuroendocrine Liver Metastases	John Hudson, MD, PhD, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Radiation Oncology	166
89	O-8	Role of Chromogranin A-derived Fragments as Biomarkers for Pancreatic Neuroendocrine Tumors (PanNET)	Valentina Andreasi, MD, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Pancreatic Surgery Unit, Pancreas Translational & Clinical Research Center	168
90	O-9	Patient Experience with Somatostatin Analog Treatments for Neuroendocrine Tumors: Insight from Qualitative Interviews	David Ray, PharmD, MBA, MPH Ipsen Biopharmaceuticals	171
91	O-10	Neuroendocrine Carcinoma of the Rectum & Anus: Patient Characteristics and Treatment Modalities.	Benjamin Ueberroth, MD, Mayo Clinic, Internal Medicine	191
92	O-11	The use of octreotide LAR in routine Canadian practice: Dosing considerations and persistence rates	Simron Singh, MD, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Division of Medical Oncology	178

### Category 8: Trials in Progress

Poster Number	Category ID	Poster Title	Poster Presenter	Abstract ID
93	T-1	Circulating tumor DNA (Ct DNA) as a biomarker in high-grade gastroenteropancreatic neuroendocrine tumor	Sarbajit Mukherjee, MD, Roswell Park Comprehensive Cancer Center, Department of Medicine	116
94	T-2	A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)	Aman Chauhan, MD, University of Kentucky, Internal Medicine/Medical Oncology	155
95	T-3	Cabozantinib in high grade neuroendocrine neoplasms	Nikolaos Trikalinos, MD, Washington University in St Louis, Internal Medicine / Medical Oncology	161
96	T-4	Randomized, parallel arm, Phase II Study of Telotristat in combination with Lutetium Lu 177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors (NETs)	Aman Chauhan, MD, University of Kentucky, Internal Medicine/Medical Oncology	188